SCHEMBL6958254

SCHEMBL6958254

COc1cccc2[nH]c(C(C)O)nc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
ALOX15 P16050 2/20 0.49
TP53 P04637 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
HPGD P15428 1/20 0.49
CYP2C19 P33261 1/20 0.49
CBFB Q13951 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MAOB P27338 1/20 0.48
ADORA2A P29274 1/20 0.48
HPSE Q9Y251 2/20 0.47
PARP1 P09874 5/20 0.43
KEAP1 Q14145 1/20 0.42
NFE2L2 Q16236 1/20 0.42
TSHR P16473 1/20 0.42
CYP1A2 P05177 1/20 0.42
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8578646 0.89 ALDH1A1 (0.41) ALDH1A1ALOX15TP53CYP3A4CYP2D6
SCHEMBL19170937 0.87 HSD17B10 (0.51) ALDH1A1ALOX15TP53CYP3A4CYP2D6
SCHEMBL24276142 0.84 CBFB (0.49) ALDH1A1ALOX15TP53CYP3A4CYP2D6
SCHEMBL31157033 0.83 ALDH1A1 (0.50) ALDH1A1ALOX15TP53CYP3A4CYP2D6
SCHEMBL477289 0.83 ALDH1A1 (0.50) ALDH1A1ALOX15TP53CYP3A4CYP2D6
SCHEMBL6650618 0.77 CYP3A4 (0.54) ALDH1A1ALOX15TP53CYP3A4CYP2D6
SCHEMBL1170818 0.76 CBFB (0.69) ALDH1A1ALOX15TP53CYP3A4CYP2D6
SCHEMBL6958259 0.75 KEAP1 (0.42) ALDH1A1ALOX15TP53CYP3A4CYP2D6
SCHEMBL4611125 0.75 ALDH1A1 (0.55) ALDH1A1ALOX15TP53CYP3A4CYP2D6
SCHEMBL4420446 0.75 ALDH1A1 (0.55) ALDH1A1ALOX15TP53CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0944616-B1 BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE DARWIN DISCOVERY LTD (GB) 2003-06-04 EP disclosed
US-20020094987-A1 Bicyclic aryl carboxamides and their therapeutic use DYKE HAZEL JOAN (GB) 2002-07-18 US disclosed
US-6353010-B1 ENZYME INHIBITORS TUMOR NECROSIS FACTOR AND PHOSPHODIESTERASE FOR ANTIINFLAMMATORY AGENTS DARWIN DISCOVERY, LTD. (GB) 2002-03-05 US disclosed
EP-0944616-A1 BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE Darwin Discovery Limited (GB) 1999-09-29 EP disclosed
WO-1998022460-A1 BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE DARWIN DISCOVERY LIMITED (GB) 1998-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020094987-A1 Bicyclic aryl carboxamides and their therapeutic use PDE3B, PDE3A, PDE2A ALDH1A1 202/4885ALOX15 849/4885TP53 4134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.